The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2024 | Improving treatment access with off-the-shelf bispecific antibodies in multiple myeloma
Monika Engelhardt, MD, University Medical Center Freiburg, Freiburg, Germany, shares her thoughts on improving treatment accessibility with off-the-shelf bispecific antibody immunotherapeutics in multiple myeloma (MM). BCMA- and GPRC5D-targeting bispecific antibodies have induced significant, durable remissions in heavily pre-treated patients. Provided that treatment-optimizing practices are employed, including step-up dosing and managing adverse side effects such as cytokine release syndrome (CRS), Dr Engelhardt suggests that off-the-shelf bispecifics be used in clinical settings. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, there are three bispecific antibodies on the market and being accessible for multiple myeloma patients. So BCMA bispecific antibodies or GPRC5D bispecific antibodies. So you give them either once a week or every two weeks or later on even less frequently. And they have induced very deep remissions. Despite those, patients have been highly treated with a median of six prior therapies, and also despite the fact that myeloma was really much on the top of a high disease burden...
Yeah, there are three bispecific antibodies on the market and being accessible for multiple myeloma patients. So BCMA bispecific antibodies or GPRC5D bispecific antibodies. So you give them either once a week or every two weeks or later on even less frequently. And they have induced very deep remissions. Despite those, patients have been highly treated with a median of six prior therapies, and also despite the fact that myeloma was really much on the top of a high disease burden. So I think this is entering a new era of using these off-the-shelf or bispecific antibodies quite readily, not only in hospitals but also in private practices. So everybody can perform this if they are very safe and familiar of how this is being done. So step-up dosing and whether CRS is evolving, so side effects. And then trying to get the disease into a very deep remission and trying to keep those patients as long on these treatments as this is possible. So we are also hearing in this session this afternoon about the pros of deep remission, but also the cons on there is quite a bit of infection. So prophylaxis, immunization, with different means and also readily knowing who has a infection and getting this patient into a hospital is very much key, and immunoglobulin infusions that are also important.
Read more...
